AstraZeneca has unveiled an at-home delivery option for its FluMist nasal spray flu vaccine, allowing parents to vaccinate their children without leaving home. This groundbreaking move aims to boost vaccination rates amid declining flu shot coverage.
A new CDC survey indicates increased vaccination rates for Tdap and MenACWY among US teens, while HPV vaccine uptake remains stagnant. Discover the latest trends and implications for public health.
AstraZeneca's FluMist Home, a nasal flu vaccine available for at-home use, aims to improve vaccination rates among children, especially those afraid of needles. Experts discuss its effectiveness and accessibility.
